Oral Care With Propolis in Pediatric Oncology Patients
Launched by IZMIR KATIP CELEBI UNIVERSITY · May 31, 2022
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
According to the data from the World Health Organization, approximately 14 million people are diagnosed with cancer every year, and this number is expected to increase further in the next 10 years. Multidisciplinary treatment consisting of chemotherapy, radiotherapy and surgery is applied in childhood cancers. In chemotherapy, the target is cancerous cells, but high doses of chemotherapeutic agents do not have selectivity. Intact tissue cells are also affected by this cytotoxicity. Mucositis develops in the patient, especially as a result of the mucosal cells being affected. Mucositis is de...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Volunteering to participate in the study
- • Receiving chemotherapy treatment for lymphoproliferative malignant disease (leukaemia, lymphoma) or other childhood solid tumour (such as central nervous system tumour, neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, hepatoblastoma, germ cell tumours)
- • Being between the ages of 2-18 (Although there is no harm in using propolis, it is inconvenient for children under the age of 2 to use honey and its by-products due to botulism)
- • No development of oral mucositis
- • The child who does not smoke
- Exclusion Criteria:
- • The patient does not receive head and neck RT (increases the incidence of oral mucositis by 40%).
- • The patient is allergic to bee products.
- * Exclusion Criteria and Practices in this Case:
- • Development of an allergic reaction to propolis (Applied oral care protocol is stopped, removed from the sample)
- • Starting RT
- • The child's need for MV support
About Izmir Katip Celebi University
Izmir Katip Celebi University is a prominent academic institution in Turkey, dedicated to advancing medical research and education. The university is committed to fostering innovation and excellence in clinical trials, leveraging its state-of-the-art facilities and a multidisciplinary team of experienced researchers and healthcare professionals. With a focus on improving patient outcomes and contributing to the global body of medical knowledge, Izmir Katip Celebi University actively engages in collaborative research initiatives, aiming to address critical health challenges through rigorous scientific inquiry and ethical practices in clinical trial management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İzmir, , Turkey
Patients applied
Trial Officials
ZUHAL ONER SIVIS, MD
Study Chair
Tepecik Research and Training Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials